Hoggatt J. Gene Therapy for "Bubble Boy" Disease. Cell. 2016 Jul 14; 166(2):263.

Citation

Hoggatt J. 2016. Gene Therapy for "Bubble Boy" Disease. Cell. 166(2):263. Pubmed: 27419862

Abstract

Adenosine deaminase (ADA) deficiency results in the accumulation of toxic metabolites that destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often referred to as the "bubble boy" disease. Strimvelis is a European Medicines Agency approved gene therapy for ADA-SCID patients without a suitable bone marrow donor.

Related Faculty

Jonathan Hoggatt, Ph.D.

Jon Hoggatt researches tissue regeneration and stem cell biology, with a particular focus on translational research to enhance bone marrow transplantation.